PLYX
Polaryx Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.04
−4.67%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +9.3%
- EBIT
- +29.7%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +70.4%
- EBIT
- -79.7%
- Net income
- +70.4%
- EPS
- -18.8%
- Free cash flow
- -53.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026